Magazine Article | December 1, 2021

Formulation Alternatives: Looking Beyond Parenteral Biologics

Source: Life Science Leader

By Matthew Pillar, Editor, BioProcess Online

In virtually any market, an eight-to-10-year CAGR forecast between 5%and 10%is good. Twenty percent is great. Thirty percent is stellar.

Coherent Market Research pegs the oral biologics market to grow at a CAGR of more than 35% through 2028.

But the mouth isn’t the only alternative approach to biologic vaccine and therapeutic administration, and tablets and capsules aren’t the only formulations making waves. The nasal epithelium presents an increasingly promising site of administration of large molecules. That’s a partial driver of the analyst expectations that the intranasal drug delivery market will hit $71.3 billion by 2026 (per Global Industry Analysts Inc.).

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: